ANI |
Up to date: Sep 05, 2026 16:59 IST
New York [US], September 5 (ANI): Weight loss drugs akin to Ozempic, Wegovy and Zepbound could also be linked to a better threat of male sample hair loss, with males already genetically predisposed to the situation dealing with a 7 per cent added threat, in accordance with a brand new examine led by researchers at NYU Langone Well being.
Revealed on-line on September 3 within the Journal of Investigative Dermatology, the peer-reviewed examine is the primary to establish a genetic hyperlink between GLP-1 exercise and an elevated threat of androgenetic alopecia, an inherited type of hair loss that sometimes follows a sample alongside the highest and entrance of the scalp.
The researchers examined the GLP1R gene, which naturally influences ranges of GLP-1 receptor proteins within the physique, and in contrast its exercise with genetic markers related to androgenetic alopecia in males.
They discovered that GLP1R genes related to naturally larger ranges of GLP-1 receptor proteins have been extra prone to be current in males with androgenetic alopecia. After accounting for hypertension, which is assumed to cut back blood circulate to the scalp and have an effect on hair follicle progress, the extra threat remained at 7 per cent.
The researchers additionally assessed different potential elements related to hair loss, together with insulin resistance and decrease testosterone ranges. The 7 per cent elevated threat linked to GLP-1 exercise remained after these elements have been thought of.
GLP-1 medicine are used to manage blood sugar and suppress urge for food, and plenty of customers have reported thinning hair as a aspect impact. Researchers have thus far largely attributed the shedding to speedy weight reduction brought on by the medicines. Hair progress typically resumes a number of months after weight stabilises.
Till now, nevertheless, a genetic connection between GLP-1 use and hair loss had solely been suspected.
“Our examine supplies the primary genetic hyperlink between GLP-1 use and an elevated threat of male-pattern hair loss from androgenetic alopecia, an affiliation lengthy suspected however till not proven scientifically,” mentioned senior investigator Lynn Petukhova, PhD, assistant professor within the Ronald O. Perelman Division of Dermatology and the Division of Inhabitants Well being at NYU Grossman Faculty of Medication.
Petukhova mentioned the findings may finally assist establish folks at larger threat of hair loss earlier than they’re prescribed GLP-1 medicines, if future experiments verify the affiliation. She additionally mentioned the findings may doubtlessly result in mixture remedies geared toward stopping hair loss.
The examine didn’t set up the organic mechanism answerable for the affiliation. Petukhova mentioned additional analysis is required to find out how GLP-1 exercise could have an effect on hair follicle progress and whether or not the findings seen in males additionally apply to ladies.
The researchers used massive publicly out there genetic databases, together with the eQTLGen database, which comprises information from 31,684 largely White women and men, and the Advanced Traits Genetics group database, comprising 205,327 largely White males.
Androgenetic alopecia is estimated to have an effect on about half of White American males over age 50 and practically the identical proportion of White American ladies over 50, notably those that are postmenopausal.
In accordance with surveys cited within the examine info, an estimated 12 per cent of Individuals have used GLP-1 medicine solely for weight reduction, together with one in 5 ladies aged 50 to 64. Since Ozempic grew to become the primary GLP-1 drug accredited by the US Meals and Drug Administration in 2020, prescriptions for the treatment have greater than tripled.
The examine was supported by Nationwide Institutes of Well being grants R01AR080796 and K01AR075111, as per Eureka Alert!
The researchers disclosed a number of trade relationships. Jerry Shapiro, MD, and Kristen Lo Sicco, MD, have beforehand served as examine investigators for hair-loss medicine and gadgets manufactured by Pfizer and Regen Labs. Lo Sicco can also be a paid advisor for Pfizer, Lilly, Ro, Priovant, Veradermics and Aquis. NYU Langone mentioned the phrases of those relationships are managed underneath its institutional insurance policies.
The examine additionally concerned researchers from the College of Pennsylvania, King’s School London and Columbia College.
The copy may also be tailored right into a shorter breaking-news model, a Google Uncover-style story, or a extra India-focused well being explainer whereas preserving the identical factual limits. (ANI)
